Bazar brings decades of experience in engineering, computer science and cyber security, AI and business intelligence on a career of successful companies.
Eden Prairie, Minnesota, May 28, 2025 (Globe Newswire) -Sanuwave Health, Inc. (the “company” or “Sanuwave”) (Nasdaq: SNWV), a leader of injury of wounded care products approved by the next generation FDA, is pleased to announce the addition of Greg Bazar to its directors of directors.
Bazar contributes decades of experience in leadership in engineering, technology and cybersecurity to the Board of Directors of Sanuwave. He currently serves as president of the Board of Syntic Systems, a company that founded to deliver advanced solutions of IT and cybersecurity. Previously, he was the first employee of the 3D-P intelligent connectivity supplier, where he played a fundamental role in the company’s growth and strategic direction, ultimately, he became president of the Board and took it through its acquisition by Epiroc, a world leader in mining and infrastructure solutions. Greg began his career in Caterpillar, gaining global experience in the use of technology to improve human innovation. He has an engineering title of the Colorado Mining School.
“All interesting parties of the future are interdisciplinary; this is the reason why Sanuwave focuses on finding drivers and leaders with unusual Venn overlap in their experience and talents. Greg conforms to this mold, providing experience in a variety of disciplines that will be important for our future route map, as well as a comprehensive record of the construction of culture that makes successful companies,” said Sanwave Cewave Frank Frank. “He is” one of us “and we hope to work with him in our mission of revolutionizing the complex care of wounds.”
“From engineering to cybersecurity, intelligent solutions have always attracted me. Sanuwave healing technology is brilliant, already measured beyond therapeutics and informative ecosystems, this is clearly the way to follow. Let’s do some noise and progress!”
Greg joined the Sanuwave Board on May 27, 2025.
The company also announced that the member of the Board for a long time, Michael Stolarski, will resign to spend more time (very necessary) with his golf game and eat elegant things.
“Mike has been an unconditional of Sanuwave since the first days, and we thank him for his invaluable contributions and his good humor over the years,” said Morgan Frank. “We will miss you, friend.”
Mr. Stolarski agreed to continue being a company’s consultant to provide continuity and help in the transition.
About Sanuwave
Sanuwave Health focuses on the research, development and marketing of its patented, non -invasive and biological systems response activators for the repair and regeneration of the skin, musculoskeletal tissue and vascular structures.
The extreme -to -end wound portfolio of Sanuwave of regenerative medicine products and product candidates help restore normal body healing processes. Sanuwave applies and investigates its patented energy transfer technologies in wound healing, orthopedic/column, aesthetics/cosmetics and heart/endovascular conditions.
Declarations with advance
This press release may contain “prospective statements” in the sense of the Law for the Reform of Private Securities Litigation of 1995, as statements related to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in rates. Prospective statements include all statements that are not historical statements regarding the intention, belief or current expectations of the company, its directors or its officials. Inverters are warned that such statements with a vision of the future do not guarantee future performance and imply risks and uncertainties, many of which are beyond the company’s control capacity. The real results may differ materially from those projected in the prospective statements. Among the risks, assumptions and key factors that can affect the operational results, performance and financial condition are risks associated with regulatory supervision, the company’s capacity to administer its capital, competition and other factors discussed in detail in the company’s periodic presentations with the stock exchange and values commission. The company does not have the obligation to update any prospective statement.
Contact: investors@sanuwave.com
